New inhaled antifungal shows promise for lung transplant patients
NCT ID NCT05037851
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called opelconazole, given as a mist through a nebulizer, to prevent a serious fungal lung infection (aspergillosis) in people who had a lung transplant. The trial involved 102 participants and compared the drug to standard care. The main goal was to see how safe and tolerable the treatment was over 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Opelconazole (nebulized antifungal drug)
What this could lead to
If successful, this could provide a safer, more effective way to prevent dangerous fungal infections in lung transplant patients.
What could go wrong
This is a small, early-phase trial focused on safety and tolerability, not yet proving the drug prevents infections. Results may not apply to all transplant patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ASPERGILLOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Site
Phoenix, Arizona, 85013, United States
-
Clinical Research Site
La Jolla, California, 92037, United States
-
Clinical Research Site
Los Angeles, California, 90095, United States
-
Clinical Research Site
Jacksonville, Florida, 32224, United States
-
Clinical Research Site
Tampa, Florida, 33606, United States
-
Clinical Research Site
Maywood, Illinois, 60153, United States
-
Clinical Research Site
New York, New York, 10016, United States
-
Clinical Research Site
The Bronx, New York, 10467, United States
-
Clinical Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Clinical Research Site
Philadelphia, Pennsylvania, 19140, United States
-
Clinical Research Site
Pittsburgh, Pennsylvania, 15213, United States
-
Clinical Research Site
Nashville, Tennessee, 37232, United States
-
Clinical Research Site
Dallas, Texas, 75246, United States
-
Clinical Research Site
Edmonton, T6G 1Z1, Canada
-
Clinical Research Site
Toronto, M5G 2N2, Canada
-
Clinical Research Site 1
Houston, Texas, 77030, United States
-
Clinical Research Site 2
Houston, Texas, 77030, United States
-
Clinical Research Site 3
Houston, Texas, 77030, United States
-
Research Site
St Louis, Missouri, 63110, United States